Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jin Medical International (ZJYL) Total Current Liabilities (2022 - 2025)

Jin Medical International's Total Current Liabilities history spans 4 years, with the latest figure at $23.8 million for Q3 2025.

  • For Q3 2025, Total Current Liabilities rose 38.73% year-over-year to $23.8 million; the TTM value through Sep 2025 reached $23.8 million, up 38.73%, while the annual FY2025 figure was $23.8 million, 38.73% up from the prior year.
  • Total Current Liabilities for Q3 2025 was $23.8 million at Jin Medical International, up from $17.2 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $23.8 million in Q3 2025 and bottomed at $5.7 million in Q3 2022.
  • The 4-year median for Total Current Liabilities is $13.0 million (2023), against an average of $13.9 million.
  • The largest annual shift saw Total Current Liabilities surged 92.19% in 2024 before it skyrocketed 38.73% in 2025.
  • A 4-year view of Total Current Liabilities shows it stood at $5.7 million in 2022, then soared by 56.46% to $8.9 million in 2023, then soared by 92.19% to $17.2 million in 2024, then skyrocketed by 38.73% to $23.8 million in 2025.
  • Per Business Quant, the three most recent readings for ZJYL's Total Current Liabilities are $23.8 million (Q3 2025), $17.2 million (Q3 2024), and $8.9 million (Q3 2023).